Immuneering (US:IMRX)2026-03-06 13:09Financial Performance - Ended 2025 with $217 million in cash, cash equivalents, and marketable securities, compared to $36.1 million at the end of 2024[4] - Net loss attributable to common stockholders for Q4 2025 was $11.6 million, or $0.18 per share, compared to a net loss of $18.1 million, or $0.58 per share, in Q4 2024[8] - Total assets increased significantly to $231,985,010 in 2025 from $52,714,413 in 2024, representing a growth of approximately 339%[18] - Current assets rose to $176,245,954 in 2025, up from $39,587,569 in 2024, marking an increase of about 344%[18] - Cash and cash equivalents surged to $128,645,025 in 2025, compared to $36,144,720 in 2024, reflecting an increase of approximately 256%[18] - Total liabilities increased to $13,501,042 in 2025 from $11,328,187 in 2024, which is an increase of about 19%[18] - Stockholders' equity grew to $218,483,968 in 2025, up from $41,386,226 in 2024, indicating a substantial increase of approximately 427%[18] - Additional paid-in capital rose to $498,658,072 in 2025, compared to $265,650,362 in 2024, representing an increase of about 88%[18] - The accumulated deficit widened to $(280,320,084) in 2025 from $(224,295,186) in 2024, reflecting a decrease in retained earnings[18] - The number of Class A common stock shares issued increased to 64,648,230 in 2025 from 31,050,448 in 2024, showing a growth of approximately 108%[18] - Total current liabilities increased to $10,073,721 in 2025 from $7,503,768 in 2024, which is an increase of about 34%[18] - The company reported no preferred stock issued or outstanding for both 2025 and 2024, maintaining a consistent capital structure in this regard[18] Research and Development - Research and Development (R&D) expenses for Q4 2025 were $9.3 million, down from $14.9 million in Q4 2024; full year R&D expenses were $42.0 million, compared to $48.0 million in 2024[8] - The company expects to dose the first patient in the pivotal Phase 3 MAPKeeper 301 trial in mid-2026[2] - Anticipated milestones include updated survival data from over 50 first-line pancreatic cancer patients in 1H 2026[4] - The company achieved alignment with FDA and EMA on the Phase 3 trial design for atebimetinib[5] Clinical Outcomes - Reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP, significantly above the 35% benchmark for standard of care[1] Market Position - Immuneering was added to the Nasdaq Biotechnology Index on December 22, 2025[5] - The cash runway is expected to fund operations into 2029[6]